| Name | Cvs Pharmacy |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 10522 Spring Green Blvd, Katy, Texas 77494 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (281) 392-3352 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.
In an effort to rein in costs, the Centers for Medicare and Medicaid Services will in 2012 perform an audit before paying for certain cardiology and orthopedic procedures in key states, including Florida.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.
› Verified 7 days ago
| NPI Number | 1538440771 |
| Organization Name | CVS PHARMACY INC |
| Doing Business As | CVS PHARMACY #02249 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 10522 Spring Green Blvd, Katy, TX 77494 |
| Phone Number | 281-392-3352 |
News Archive
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.
In an effort to rein in costs, the Centers for Medicare and Medicaid Services will in 2012 perform an audit before paying for certain cardiology and orthopedic procedures in key states, including Florida.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.
› Verified 7 days ago
News Archive
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.
In an effort to rein in costs, the Centers for Medicare and Medicaid Services will in 2012 perform an audit before paying for certain cardiology and orthopedic procedures in key states, including Florida.
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.
› Verified 7 days ago
A Hug Away Medical Supplies Type: Medicare Supplier Location: 1203 Avenue D, Katy, Texas 77493 Phone: (281) 437-1983 | |
Atoms Pharmacy Llc Type: Long Term Care Pharmacy Location: 2333 Fry Rd, Katy, Texas 77449 Phone: (832) 974-4915 | |
Berkeley Eye Institute, P.a Type: Medicare Supplier Location: 21502 Merchants Way, Katy, Texas 77449 Phone: (281) 579-6777 | |
Brite Healthcare Type: Durable Medical Equipment & Medical Supplies Supplier Location: 21400 Provincial Blvd, Katy, Texas 77450 Phone: (281) 945-4000 | |
Brookshire Brothers Pharmacy # 9 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5249 Franz Rd, Katy, Texas 77493 Phone: (281) 391-7051 |